Mimi Hu, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1497962252
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Eli Lilly accounts for 66.5% of it on its own, with 2 other manufacturers making up the rest.
Across 14 payments — averaging $1316.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$12K
- Blueprint Medicines Corporation$6K
- Amgen$15
Across 3 payments — averaging $18,484 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$54K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$8,15344%
- Speaking & faculty fees$9,44151%
- Travel & lodging$6864%
- Food & beverage$1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 11 | $12,255 |
| Blueprint Medicines Corporation | 2 | $6,160 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GAVRETO$2,800
How this compares
$18,430 in reported general payments places this provider in the 75th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GavretoPralsetinib | 29 | $507,444 |
| MekinistTrametinib Dimethyl Sulfoxide | 28 | $421,733 |
| TafinlarDabrafenib Mesylate | 29 | $405,150 |
| LenvimaLenvatinib Mesylate | 12 | $289,168 |
| CaprelsaVandetanib | 18 | $214,362 |
| Everolimus | 14 | $103,532 |
| SynthroidLevothyroxine Sodium | 26 | $1,769 |
| Levothyroxine Sodium | 37 | $656 |
| LevoxylLevothyroxine Sodium | 15 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Blueprint Medicines CorporationGavreto | $6,160 | $507,44429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Rocio HarbisonHouston$989K
- Andres SplenserHouston$923K
- Daniel TungHouston$753K
- Damaris VegaHouston$565K
- Steven PetakHouston$452K
- Amin JamalHouston$217K
- Laila TabatabaiHouston$207K
- Rakesh PatelHouston$187K
- Veena WatweHouston$157K
- Tiana ShiverHouston$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.